The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
As the licencee is a Private company, is it correct to say they can’t do a conventional raise. Therefore are we looking at a company that will raise funds via a biotech crowdfunding platform? If so it might not be so difficult to identify them.
I was surprised to read on the Advfn board
That Stephen Parker is part of OPUS Corporate Finance, which is correct. Considering what Opus do, (capital raising) RF seems a bizarre choice.
https://opuscf.com/people/dr-stephen-b-parker/
Hi HBD,
2023-11-17.Application filed by シエラ オンコロジー エルエルシー
Application filed by: That translate to Sierra Oncology, surprised they are filing a patent in November last year??!
Aber, I don’t think any company is going make an offer in the £5-6 range per share, with a sp 40p they would probably offer 150-200% premium, say £1.50 ish per share. Without data there’s unlikely to be any offers as yet. Just amazed how much a £3m equity deal has wiped off the market cap. If that was the best offer on the table……….
It’s been a long time getting here. However from reading the below, clearly Sareum have tried to overcome as many of the common areas of failure. Personally I feel they have taken the correct approach and as such we have a better chance of success. Have a good weekend all.
Good read ref Trials failure. Particular mention of kinase inhibitor (2.2)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739/#:~:text=It%20is%20also%20worth%20noting,candidates%20in%20the%20preclinical%20stages.
Unfortunately the SRA737 deal won’t impress to many people. Upfront is low and the upper figures are worth nothing until something materialises. Having said that, I don’t feel it’s a bad deal. GSK may have returned it but that doesn’t mean there’s no potential. Sierra paid Gilead an upfront fee of $3 million for momelotinib and GSK paid $2 billion to get hold of it. Back to the waiting game….. red or black?
Spot on Luton. It is what it is. Do I wish I’d sold and banked c£400k during the covid spike?, in hindsight yes. But at the end of the day it’s a gamble and hopefully we will one day beat the previous highs, but who knows. It’s AIM, it’s a gamble, isn’t that why most of us invested in the first place? Adds a bit of excitement to life.